Folate and Folic Acid: Why This B Vitamin Matters

Folate vs Folic Acid: Key Differences Explained

The terms 'folate' and 'folic acid' are often used interchangeably, but they refer to chemically distinct compounds with important differences in bioavailability and metabolism. Folate is the generic term for a family of naturally occurring B9 vitamins found in food — primarily in the form of polyglutamylated tetrahydrofolates, which are the biologically active forms. Folic acid is a fully oxidized synthetic form used in supplements and food fortification that does not naturally occur in food. Folic acid is actually more bioavailable than food folate (estimated at approximately 85% vs 50%), but it requires enzymatic reduction to be used by the body.

Dietary Folate Equivalents (DFE) is the standardized unit created to account for this difference in bioavailability: 1 mcg DFE = 1 mcg food folate = 0.6 mcg folic acid (when taken with food) = 0.5 mcg folic acid (taken on an empty stomach). The adult RDA of 400 mcg DFE reflects average dietary intakes from mixed food sources.

A third form — 5-methyltetrahydrofolate (5-MTHF, or methylfolate) — is the predominant circulating form in the blood and the form that enters cells for metabolic use. Folic acid must be converted through two enzymatic reduction steps (DHFR and MTHFR) before it can be used, while 5-MTHF is already in the active form and bypasses these steps entirely. This distinction has gained clinical importance with the discovery that common variants in the MTHFR gene reduce the efficiency of this conversion, potentially leaving a fraction of ingested folic acid unmetabolized in the bloodstream.

DNA Synthesis, Cell Division, and Growth

Folate's most fundamental biological role is in the synthesis of purines and thymidylate — the building blocks of DNA and RNA. Specifically, folate coenzymes (5,10-methyleneTHF) donate single carbon units in the methylation of dUMP to dTMP (catalyzed by thymidylate synthase) and in the synthesis of purine bases. Without adequate folate, DNA synthesis stalls, and rapidly dividing cells — including hematopoietic cells in the bone marrow — accumulate DNA damage and fail to divide normally.

This impairment of DNA synthesis is the basis of megaloblastic anemia — the classic manifestation of folate (and vitamin B12) deficiency. In megaloblastic anemia, red blood cell precursors cannot properly replicate their DNA, leading to abnormally large cells (megaloblasts) with impaired nuclear maturation. The resulting large, malformed red blood cells (macro-ovalocytes) and hypersegmented neutrophils on a blood smear are the diagnostic hallmarks. The anemia produces fatigue, weakness, and shortness of breath due to impaired oxygen-carrying capacity.

Because folate is required for all rapidly dividing cells, deficiency impairs not only red blood cell production but also the renewal of intestinal epithelial cells (causing glossitis and gastrointestinal symptoms), immune cell development, and fetal tissue growth during pregnancy. Cancer cells, which divide at high rates, also require substantial folate — a relationship that was exploited in the development of methotrexate and other antifolate chemotherapy drugs, which block DHFR and starve cancer cells of functional folate.

Folate in Pregnancy and Neural Tube Prevention

The most well-established and consequential application of folate nutrition is the prevention of neural tube defects (NTDs) — serious birth defects affecting the development of the brain and spine. Neural tube closure occurs between 18 and 28 days post-conception — typically before a woman knows she is pregnant — making pre-conception folate status critical. NTDs include anencephaly (absence of most of the brain, invariably fatal), spina bifida (incomplete spinal cord closure), and encephalocele.

Multiple large randomized controlled trials in the 1980s and 1990s established that periconceptional folic acid supplementation reduces NTD risk by 50–70%. This evidence prompted the US FDA to mandate folic acid fortification of enriched grain products beginning in 1998, which has resulted in a 25–30% reduction in NTD incidence in the US population. The CDC recommends that all women of reproductive age who could become pregnant consume 400 mcg of folic acid daily, increasing to 600–800 mcg daily for those actively trying to conceive and during the first trimester of pregnancy.

Beyond NTDs, adequate folate during pregnancy is associated with reduced risk of congenital heart defects, cleft lip and palate, preterm birth, and low birth weight. Some research suggests that maternal folate status during the second and third trimesters influences infant cognitive development and language outcomes, possibly through effects on neuronal migration and myelination. Women who have previously had a pregnancy affected by an NTD are typically prescribed 4,000 mcg (4 mg) of folic acid daily, as they are at significantly higher risk of recurrence.

MTHFR Gene Variants and Folate Metabolism

The MTHFR gene encodes methylenetetrahydrofolate reductase, the enzyme responsible for converting 5,10-methyleneTHF to 5-methylTHF (the circulating form of folate that donates methyl groups for the methylation cycle). Two common polymorphisms — C677T and A1298C — reduce this enzyme's activity. The C677T homozygous variant (TT genotype) reduces MTHFR activity by approximately 70%, while the heterozygous variant (CT) reduces it by about 35%. The C677T TT genotype is found in approximately 10–15% of North Americans of European descent, and up to 25% of Mexicans and Italian populations.

Individuals with the TT genotype are more likely to have elevated plasma homocysteine (because the methylation cycle is impaired when 5-MTHF production is reduced), lower red blood cell folate, and potentially higher requirements for active folate forms. There is debate about whether people with MTHFR variants should specifically take methylfolate (5-MTHF) supplements rather than folic acid, but current consensus from major health organizations is that standard folic acid supplementation is adequate for most individuals with MTHFR variants, particularly given the additional enzymatic steps that can bypass the MTHFR bottleneck.

However, in individuals with C677T TT genotype who also have elevated homocysteine despite adequate folic acid intake, switching to methylfolate may be clinically beneficial. Homocysteine above 15 micromol/L is independently associated with cardiovascular disease risk, cognitive decline, and (in pregnancy) adverse outcomes including placental abruption. B12 and B6 are also required for homocysteine remethylation and transsulfuration respectively, so elevated homocysteine should be investigated across all three B vitamins.

Best Dietary Sources of Folate

Folate is found naturally in a wide variety of foods, with legumes, leafy greens, and fortified grains being the primary contributors to intake in most populations. Cooked lentils are the single richest common food source: one cup provides 358 mcg DFE (90% of the RDA). Cooked black-eyed peas provide 358 mcg per cup; chickpeas provide 282 mcg per cup; kidney beans provide 230 mcg per cup. Legumes are therefore a highly practical strategy for meeting folate needs.

Dark leafy greens are excellent sources: cooked spinach provides 263 mcg DFE per cup; romaine lettuce provides 64 mcg per cup; asparagus provides 268 mcg per cooked cup. Fortified breakfast cereals can provide 100–400 mcg DFE per serving, making them a convenient folate source particularly in populations with low vegetable intake. Other notable sources include avocado (163 mcg per fruit), papaya (115 mcg per cup), and broccoli (168 mcg per cooked cup).

Folate is heat-sensitive and water-soluble; cooking can destroy 50–80% of food folate. Steaming rather than boiling vegetables, and using cooking water in soups or sauces, preserves more folate. Raw consumption (salads, smoothies) maximizes folate intake from vegetables. Freezing has relatively little effect on folate content compared to cooking.